• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Fujifilm Partners with Us2.ai to Provide AI-Automated Echocardiography Analysis for Cardiologists

by Jasmine Pennic 03/24/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– FUJIFILM Healthcare, a provider of diagnostic and enterprise imaging solutions, has announced a strategic partnership with Us2.ai, a pioneer in AI-automated echocardiography solutions. 

– The collaboration aims to integrate Us2.ai’s artificial intelligence (AI)-driven, automated clinical workflow solution into Fujifilm’s LISENDO 880 cardiovascular ultrasound system, revolutionizing cardiac diagnostics.

– The integration of Us2.ai’s software with the LISENDO 880 ultrasound system will enable fully automated analysis and reporting of echocardiograms, providing comprehensive cardiac measurements crucial for the diagnosis of heart disease.

Cardiovascular Disease Impact

Cardiovascular disease (CVD), the leading cause of mortality worldwide, relies heavily on echocardiography for non-invasive heart imaging. While echocardiography is considered safe, reliable, and cost-effective, it is also a highly manual and time-consuming procedure, requiring expert operators who are currently in short supply, contributing to sonographer workforce shortages.

Us2.ai’s echocardiographic analysis software addresses this critical challenge. Studies published in the Journal of Echocardiography have demonstrated that Us2.ai’s technology can reduce measurement and report creation time by up to 70% compared to manual methods.

Traditional echocardiography workflows involve image capture followed by manual or semi-automated measurements before data is sent to an image server. Us2.ai’s software streamlines this process by automatically analyzing images acquired on the LISENDO 880 ultrasound system, eliminating the need for manual measurements. The AI identifies heart chambers, calculates clinically significant measurements, and provides disease indication conclusions based on international guidelines for physician decision support.

“Echo images are the gold standard for non-invasive cardiac imaging, however the average time to complete an exam can take anywhere from 40 to 90 minutes, plus reporting time. AI has the ability to dramatically reduce this time burden, provide cardiologists with intelligent insights, and allow for more patients to get scanned,” said Hideyuki Honda, Vice President, Ultrasound Business Unit and Business Development, FUJIFILM Healthcare Americas Corporation. “Fujifilm is thrilled to partner with Us2.ai to integrate their sophisticated AI with our cutting-edge LISENDO 880, providing cardiologists with exceptional, AI-driven automation analysis of the heart.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |